🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Agostina Nardone

Agostina Nardone

Harvard University

ORCID: 0000-0003-3277-1101

Also affiliated with Dana-Farber Cancer Institute, AstraZeneca (Spain), Hospital of Prato

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 13 papers. Top paper: “Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer”.

Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2305

N/A

0.918DataRank · unranked

28 citations

Tianyu Li, Albert Grinshpun, Tim H. H. Coorens, Douglas Russo, Leilani Anderson +16 more

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2975

N/A

0.907DataRank · unranked

35 citations

Agostina Nardone, Douglas Russo, Zsuzsanna Nagy, Capucine Héraud, Albert Grinshpun +26 more

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

Proceedings of the National Academy of Sciences(2016)10.1073/pnas.1612835113

N/A

0.784DataRank · unranked

185 citations

Rinath Jeselsohn, Resel Pereira, Emporia F. Hollingsworth, Chad J. Creighton, Fugen Li +22 more

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Cancer Research(2023)10.1158/0008-5472.can-23-1711

N/A

0.596DataRank · unranked

15 citations

Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi +36 more

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer

JCI Insight(2025)10.1172/jci.insight.188051

N/A

0.385DataRank · unranked

12 citations

Zachary M. Sandusky, Douglas Russo, David Zak, Agostina Nardone, Delia Friel +11 more

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer

npj Breast Cancer(2024)10.1038/s41523-024-00647-1

N/A

0.241DataRank · unranked

4 citations

Douglas Russo, Wen Ma, Ana Verma, Francisco Hermida-Prado, Shira Sherman +13 more

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.29.486217

N/A

0.130DataRank · unranked

1 citations

Xintao Qiu, Ariel Feiglin, Xiaoyong Fu, Sándor Spisák, Avery Feit +20 more

Combination of fulvestrant and chemotherapy in ESR1 Y537S mutant breast cancer cells and potential synergy mechanism related to p53 wildtype.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1065

N/A

0.104DataRank · unranked

1 citations

Francisco Hermida‐Prado, Cristina Guarducci, Avery Feit, Agostina Nardone, Gabriella Cohen +6 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603.v1

N/A

0DataRank · unranked

0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603

N/A

0DataRank · unranked

0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0257

N/A

0DataRank · unranked

11 citations

Shayna Stein, Agostina Nardone, Weihan Liu, Wen Ma, Gabriella Cohen +5 more

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Cell Reports(2023)10.1016/j.celrep.2023.112821

N/A

0DataRank · unranked

22 citations

Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J. Shea, Sarmistha Nanda +17 more

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-19-4191

N/A

0DataRank · unranked

94 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more